Abstract
If it were possible to assume adequate exposure to an active agent, anything less than complete regression must indicate a degree of resistance. In practice, varying degrees of resistance may be seen at initial presentation or subsequently. These range from no response at all, initial tumour regression followed by stabilisation, to stabilisation without regression. Between patients with identical tumours there may be profound differences in the time taken to respond to identical therapies. To attribute either incomplete response or delay to inherent tumour resistance makes many assumptions. Pharmacological explanations, are frequently quoted as possible mechanisms contributing to reduced effectiveness of cancer treatment. In practice none of these factors can be implicated with certainty, and the activity of a drug regimen is assessed on the basis of a reduction in tumour volume. Clinical evidence of response, therefore, is virtually the sole means by which resistance may be assessed with any applicability to the individual tumour within the environment of the particular host. In vitro assays using the influence of drugs on the growth of tumour stem cells or the influence upon xenografts, may give sane indication, but in practice while resistance can be predicted with 90% certainty, the selection of definitely potent agents within the host is much less successful (1).
Keywords
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Alberts D.S., Salmon S.E., Chen H. S. G., Surwit E. A., Soehnlen B., Young L., Moon T. E. In vitro clonogenic assay for predicting response of ovarian cancer to chemotherapy. Lancet(2): 340–342, 1980.
Carter S. K. Cancer chemotherapy: new developments and changing concepts. Drugs(20): 375–397, 1980.
Fisher R. I., Chabner B. A., Myers C. E. Phase II study of high dose methotrexate in patients with advanced malignant melanoma. Cancer Treat Rep(63): 147–148, 1979.
Lazarus H. M., Herzig R. H., Graham-Pole J., Wolff S. N., Phillips G. L., Strandjord S., Hurd D., Forman W., Gordon E. M., Coccia P., Gross S., Herzig G. P. Intensive melphalan chemotherapy and cryopreserved autologous bone marrow transplantation for the treatment of refractory cancer. Jnl CIin Oncol(1): 359–367, 1983.
McElwain T. J., Powles R. L. High-dose intravenous melphalan for plasma-cell leukaemia and myeloma. Lancet (2): 822–824, 1983.
Souhami R. L., Harper P. G., Linch D. C., Goldstone A. H., Richards J. D. M., Trask C., Tobias J. S., Spiro S. G., Geddes D. M. Single agent high dose cyclophosphamide with autologous bone marrow transfusion (ABMT) as initial treatment for small cell carcinoma of the bronchus (SCCB) (Abstract). The III World Conference on Lung Cancer(235): 169, 1982.
Yap H. Y., Blumenschein G. R., Yap B. S., Hortobagyi G. N., Tashima C. K., Wang A. Y., Benjamin R. S., Bodey G. P. High dose methotrexate for advanced breast cancer. Cancer Treat Rep(63): 757–761, 1979.
Jaffe N. American Journal of Surgery(133):405,1977.
Bruckner H. W., Wallach R., Cohen C. J., Deppe G., Kabakow B., Ratner L., Holland J. F. High-dose platinum for the treatment of refractory ovarian cancer. Gynecologic Oncology(12): 64–67, 1981.
Ling V. Genetic aspects of drug resistance in somatic cells. In: Schabel F. M. (ed) Antibiotics and chemotherapy. S. Karger, Basel, 1978, pp 191–200.
Biedler J. L. et al. J. Cell Biochem. Suppl 6 (30), 1982.
Henderson T. C., Gelman R., Canellos G. P., Frei E. III. Prolonged disease-free survival in advanced breast cancer treatment with “super-CMF” adriamycin: An alternating regimen employing high-dose methotrexate with citrovorum factor rescue. Cancer Treat Rep(65): 67–75, 1981.
Smith J. Personal communication.
Longo D. L., Young R. C., DeVita V. T. What is so good about the “good prognosis” lymphoma. In: Williams C. J., Whitehouse J. M. A. (eds) Recent Advances in Clinical Oncology. Churchill Livingstone, Edinburgh, 1982, pp 223–231.
DeVita V. T. The relationship between tumor mass and resistance to chemotherapy. Cancer(51): 1209–1220, 1983.
Hedley D. W., Millar J. L., McElwain T. J., Gordon M. Y. Acceleration of bone-marrow recovery by pre-treatment with cyclophosphamide in patients receiving high-dose melphalan. Lancet(2): 966–967, 1978.
Millar J. L., Phelps T. A., Carter R. L., et al. Cyclophosphamide pretreatment reduces the toxic effect of high dose melphalan on intestinal epithelium in sheep. Eur J Cancer(14)1283–1285,1978.
Editor information
Rights and permissions
Copyright information
© 1984 Martinus Nijhoff Publishing, Boston
About this chapter
Cite this chapter
Whitehouse, J.M.A. (1984). Clinical Drug Resistance. In: Harrap, K.R., Davis, W., Calvert, A.H. (eds) Cancer Chemotherapy and Selective Drug Development. Developments in Oncology, vol 23. Springer, Boston, MA. https://doi.org/10.1007/978-1-4613-3837-6_1
Download citation
DOI: https://doi.org/10.1007/978-1-4613-3837-6_1
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4613-3839-0
Online ISBN: 978-1-4613-3837-6
eBook Packages: Springer Book Archive